dt

DT-061, an orally bioavailable protein phosphatase 2A (PP2A) activator, may be used in the therapy of KRAS-mutant and MYC-driven tumorigenesis.

DT204 is an SCFSkp2 inhibitor that reduces the binding of Skp2 to Cullin-1 and Commd1. It can be used to study multiple myeloma.

(1S,2S,3R)-DT-061, an enantiomer of DT-061, is an orally bioavailable activator of PP2A.

5'-O-TBDMS-dT is a nucleoside characterized by its protective and modification effects.

DMT-dT Phosphoramidite is commonly utilized in DNA synthesis.

DT-2 acetate, a selective cGMP-dependent protein kinase (PKG) inhibitor, is a mouse monoclonal antibody targeting canine thymocytes.DT-2 acetate inhibits PKG-catalyzed phosphorylation, reverses 8-Br-cGMP-induced expansion, and can be used to study immune disorders.

5'-O-DMT-dT (5'-O-(4,4'-Dimethoxytrityl)thymidine) is a nucleoside derivative used in oligonucleotide synthesis.

Vadimezan (DMXAA) is a vascular disrupting agent, a murine STING agonist, and an inducer of cytokines such as type I IFN. Vadimezan has antitumor activity and induces a rapid cessation of blood flow in tumors without affecting blood flow in normal tissues.

SMAP-2 is an orally bioavailable activator of phosphatase 2A (PP2A) which binds to the PP2A Aα scaffold subunit to drive conformational changes in PP2A. It inhibits the growth of KRAS-mutant lung cancers .

Bucladesine is a cyclic nucleotide derivative which mimics the action of endogenous cAMP and is capable of permeating the cell membrane. Bucladesine is a phosphodiesterase inhibitor. The compound is used in a wide variety of research applications because

DT2216 inhibits various Bcl-XL-dependent leukemias and cancer cells, but is significantly less toxic to platelets.DT2216 is a selective B-cell lymphoma, extremely large (BCL-XL), proteolytic targeting chimera (PROTAC).DT2216 targets bcl-XL to the Von Hipp

Dth is a proteolysis-targeting chimera (PROTAC) composed of the fluorescent RNA probe DFHBI and the immunomodulatory compound thalidomide.

DT-23 is a potent antifungal agent with a MIC50 of 15 μg/mL. It inhibits recombinant Arg1 and Kcs1, with IC50 values of 0.6 μM and 0.68 μM, respectively.

TPA-dT is a thymidine analogue featuring a tris[(2-pyridyl)methyl]amine moiety. It is utilized for the modification of siRNA. The siRNA modified with TPA remains functionally inactive and cannot silence gene expression until the TPA component is removed upon exposure to Cu(I), subsequently activating its functionality.

DT-6, a potent TGF-β1 inhibitor, impedes M2 macrophage-induced epithelial-to-mesenchymal transition and the invasive migration of cancer cells, thereby showing potential for cancer research applications [1].

DT-2 serves as a potent, selective inhibitor of cGMP-dependent protein kinase (PKG), with a Ki of 12.5 nM, effectively hindering PKG-catalyzed phosphorylation [1].

DT-3 acetate is a cell-permeable peptide that acts as an inhibitor of protein kinase G (PKGIα), effectively blocking the cGMP-PKG signaling pathway.

3'-NH-Tr-2',3'-dT-5'-CE-Phosphoramidite is a specialized phosphoramidite compound used in the synthesis of oligonucleotides and nucleic acid analogs. It plays a role in research focused on antiviral and anticancer applications.

Selodenoson (RG-14202) is a selective adenosine A1 receptor agonist used to slow the heart rate in patients with atrial fibrillation and to treat arrhythmias.

DT-3, a membrane-permeable inhibitory peptide, targets protein kinase G Iα and guanylyl cyclase ?. It effectively blocks the cGMP–PKG signalling pathway [1].

Ap4dT serves as an inhibitor of human adenylate kinase isozyme 1 (hAK1), effectively suppressing the synthesis of ATP and ADP, with IC50 values of 42 μM and 38 μM, respectively.

Ap5dT is an inhibitor of cytosolic thymidine kinase and mitochondrial enzyme, with Ki values of 0.12 μM and 0.50 μM, respectively. This compound is utilized in research related to acute myeloid leukemia.

EMDT oxalate, a selective 5-HT6 agonist, exhibits antidepressant effects.

FKBP12 PROTAC dTAG-7 (dTAG-7) is a heterobifunctional compound that selectively degrades the BET bromodomain transcriptional co-activator BRD4 by linking BET bromodomains to the E3 ubiquitin ligase CRBN. It also functions as a degrader of FKBP12F36V when FKBP12F36V is expressed in-frame with a targeted protein.